Sirona - Redefining obesity treatments. A novel hydrogel with long stomach retention times.
Lead Participant:
OXFORD MEDICAL PRODUCTS LIMITED
Abstract
**Oxford Medical Products (OMP)** aims to address the medical pandemic of excessive weight. Over 1.9 billion adults are overweight, it is the fifth biggest risk to life globally, accounting for 5% of global deaths. OMP's vision is to enable safe, effective and affordable weight loss. OMP is led by a team of scientists, medical professionals and entrepreneurs who have come together to solve one of the world's toughest and most urgent challenges.
OMP's innovation, **Sirona**, is a self-expanding hydrogel which occupies space in the stomach, reducing hunger, leading to significant weight loss. Once swallowed, the proprietary hydrogel is formulated to:
? expand rapidly in the stomach, resulting in a feeling of fullness
? stay in the stomach for a prolonged period, so it is effective 24/7
? break down and pass naturally, ensuring safety.
OMP's hydrogel has been designed to remain in the stomach's harsh environment that suppresses appetite for weeks. Sirona then breaks down and passes naturally.
These properties create a novel, breakthrough solution to help people achieve meaningful weight-loss. It has the same mode of action as bariatric surgery, currently the most effective form of treatment, but is designed to be affordable, and as effective as surgery without the risks. In this project, OMP is collaborating with University Hospital Southampton NHS Trust, to optimise and develop Sirona for use in weight-loss.
Sirona offers significant socioeconomic impacts including, significant healthcare savings, improving patients' quality of life, reducing the environmental impact of clinical pathways, and improving accessibility to healthcare treatments.
These benefits will contribute towards achieving domestic and international governments' agendas. The Department of Health and Social Care published the UK government's 'Tackling Obesity' strategy, setting out the agenda to tackle obesity and help adults and children to live healthier lives.
OMP's innovation, **Sirona**, is a self-expanding hydrogel which occupies space in the stomach, reducing hunger, leading to significant weight loss. Once swallowed, the proprietary hydrogel is formulated to:
? expand rapidly in the stomach, resulting in a feeling of fullness
? stay in the stomach for a prolonged period, so it is effective 24/7
? break down and pass naturally, ensuring safety.
OMP's hydrogel has been designed to remain in the stomach's harsh environment that suppresses appetite for weeks. Sirona then breaks down and passes naturally.
These properties create a novel, breakthrough solution to help people achieve meaningful weight-loss. It has the same mode of action as bariatric surgery, currently the most effective form of treatment, but is designed to be affordable, and as effective as surgery without the risks. In this project, OMP is collaborating with University Hospital Southampton NHS Trust, to optimise and develop Sirona for use in weight-loss.
Sirona offers significant socioeconomic impacts including, significant healthcare savings, improving patients' quality of life, reducing the environmental impact of clinical pathways, and improving accessibility to healthcare treatments.
These benefits will contribute towards achieving domestic and international governments' agendas. The Department of Health and Social Care published the UK government's 'Tackling Obesity' strategy, setting out the agenda to tackle obesity and help adults and children to live healthier lives.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| OXFORD MEDICAL PRODUCTS LIMITED | £1,121,849 | £ 785,294 |
Participant |
||
| UNIVERSITY HOSPITAL SOUTHAMPTON NHS TRUST | £457,214 | £ 457,214 |
| UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST |
People |
ORCID iD |
| Camilla Easter (Project Manager) |